<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>30711</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_pmc">30711</infon><infon key="article-id_pmid">11299059</infon><infon key="article-id_publisher-id">AR-3-3-183</infon><infon key="fpage">183</infon><infon key="issue">3</infon><infon key="journal-title">Arthritis Research</infon><infon key="kwd">Dehydroepiandrosterone sulfate inflammatory arthritis</infon><infon key="lpage">188</infon><infon key="name_0">surname:Dessein;given-names:Patrick H</infon><infon key="name_1">surname:Joffe;given-names:Barry I</infon><infon key="name_2">surname:Stanwix;given-names:Anne E</infon><infon key="name_3">surname:Moomal;given-names:Zubair</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">3</infon><infon key="year">2001</infon><offset>0</offset><text>Hyposecretion of the adrenal androgen dehydroepiandrosterone sulfate and its relation to clinical variables in inflammatory arthritis</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>134</offset><text>Rheumatoid arthritis has been associated with hypothalamic-pituitary underactivity, which could affect the way in which drugs are administered and treated.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>2007</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2020</offset><text>Diarrhoea, pain, fever, and chills have been reported in patients with inflammatory arthritis (IRA). These conditions are associated with the adrenal androgen dehydroepiandrosterone sulphate (ADH-DHEAS), a naturally occurring steroid hormone. Adderall and dexmedetomidine are the two main agents used to treat IRA. DHEAS-DHEAS is associated with increased risk for cardiovascular disease, cancer, and mortality.

This study examined the association between ADH-DHEAS and clinical variables in inflammatory arthritis (IRA). In a randomized crossover study, patients with IRA who received either adderall or dexmedetomidine (ADX) were compared to patients</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2903</offset><text>In a study conducted by Masi et al. and in another by Heikilla, it was observed that DHEAS concentrations were reduced before the onset of menopausal women, but these results may be due to differences in laboratory testing methods or underlying genetic traits.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4027</offset><text>We conducted a study in which 87 patients with IA (RA, spondyloarthropathy [Spa], or undifferentiated inflammatory arthritis [UIA]) were subjected to this treatment and found that the acute-phase response, previous glucocorticoid usage, current NSAID treatment, duration of disease, and insulin resistance were all contributing factors to lowered serum DHEAS concentrations in IAO.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>4478</offset><text>Materials and methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4500</offset><text>Patients, controls, and investigations</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4539</offset><text>Eighty-seven consecutive nondiabetic patients were enrolled. Their age (mean &#177; SD) was 49 &#177; 14 years (range 18&#8211;81). Eighty were Caucasian and 7 were Asian. Fifty-four were women, of whom 26 had RA (FRA), 14 Spa (FSpa), and 14 UIA (FUIA). Of the 33 men, 12 had RA (MRA), 15 Spa (MSpa), and 6 UIA (MUIA). The duration of disease (mean &#177; SD) was 4.8 &#177; 7.8 years. Patients with RA met the 1987 criteria of the American Rheumatism Association for the classification of RA and patients with Spa met the criteria of the European Spondyloarthropathy Study Group (ESSG) for the classification of spondyloarthropathy. Patients with UIA had swelling of at least two joint areas for a minimum of 6 weeks without meeting the criteria for either RA or Spa. Patients who had used glucocorticoids within the previous 2 months or who were taking agents known to affect insulin sensitivity or lipid metabolism were excluded. Twenty-six patients were on no medication. Agents taken were NSAIDs (n = 51), opioid agonists of low efficacy (n = 7), paracetamol (n = 6), methotrexate (n = 5), sulfasalazine (n = 4), misoprostol (n = 3), lansoprazole (n = 2), clonazepam (n = 2), mianserin (n = 2), alendronate (n = 1), and amitryptiline (n = 1). Glucocorticoids had been taken by 12 patients (6 with FRA, 2 with FUIA, 1 with MRA, 2 with MSpa, and 1 with MUIA).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5882</offset><text>The duration of disease was recorded and the body mass index (kg/m2) determined in each patient. Fasting blood samples were taken (between 0800 and 1000) for determination of the erythrocyte sedimentation rate (ESR), serum DHEAS (chemiluminescent enzyme immunoassay; Diagnostic Products Co, Los Angeles, CA, USA), lipids and insulin (microparticle enzyme immunoassay on the Axsym system; Abbott, IL, USA), and plasma glucose. The intra-assay and interassay coefficients of variance were, respectively, 1.9% and 1.2% for insulin, and 8.2% and 12.0% for DHEAS. Insulin resistance was estimated by the homeostasis-model assessment (HOMAIR) using the formula fasting serum insulin (&#956;U/ml) &#215; fasting plasma glucose (mmol/l)/22.5. Normal values for DHEAS were obtained from 134 age-matched healthy women (mean age 48 &#177; 17 years) and 149 age-matched healthy men (mean age 52 &#177; 16 years).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6767</offset><text>Statistical analyses</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6788</offset><text>Statistical analyses were made using the Statistical Package for the Social Sciences (SPSS) program. DHEAS concentrations were compared between patients and controls using the one-way analysis of variance (ANOVA). Multiple intergroup (FRA, FSpa, FUIA, MRA, MSpa, MUIA) comparisons were done by the one-way ANOVA and the Bonferroni post hoc test. The dependencies of DHEAS levels on the ESR, previous glucocorticoid usage, current NSAID treatment, duration of disease, and were evaluated using simple linear regression HOMAIR analyses and analyses of covariance. Results were expressed as mean &#177; SD except in boxplots representing DHEAS concentrations in the controls.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>7457</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>7465</offset><text>DHEAS concentrations in patients and controls</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>7511</offset><text>The DHEAS concentrations in patients and controls are reported in Table 1 and Figs 1 to 4. DHEAS concentrations were significantly lower in both women and men with IA than in their respective controls, and in 14 women (26%) and 10 men (30%) with IA, these concentrations fell below the extreme ranges (Figs 1 and 2) found in age-matched controls. The values found for the various subsets of disease are given in Table 2. Multiple intergroup comparisons of DHEAS concentrations revealed no significant differences apart from higher levels in MSpa than in MUIA (P = 0.04). Even in patients with MSpa, DHEAS concentrations were lower than in male controls (4.61 &#177; 1.87 vs 6.19 &#177; 4.12 &#956;mol/l, P &lt; 0.001). This difference remained equally significant after age was controlled for.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>8290</offset><text>The dependencies of DHEAS on clinical variables</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>8338</offset><text>The dependencies of DHEAS on clinical variables in patients with IA are represented in Tables 3 and 4. None of the evaluated variables contributed significantly to the variance of DHEAS concentrations, except for NSAID treatment in men with IA. After we had controlled for the ESR, previous glucocorticoid usage, duration of disease, current NSAID treatment, and HOMAIR, the differences in DHEAS concentrations between patients and controls were markedly attenuated in women (P = 0.050) and were no longer present in men (P = 0.133).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>8872</offset><text>Since the acute-phase response may not correlate with disease activity in inflammatory arthritides other than RA, a subgroup analysis was made in the 26 patients with FRA (Table 5). In these, previous glucocorticoid usage predicted low DHEAS concentrations. However, even when this variable was controlled for, DHEAS concentrations remained lower in FRA than in female controls (P = 0.037).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>9263</offset><text>Similarly, since DHEAS concentrations were higher in MSpa than in MUIA, a subgroup analysis was made (Table 6). In the MSpa patients, the HOMAIR and NSAID treatment accounted for 15.2% and 16.7%, respectively, of the variance in DHEAS concentrations. After the respective variables were controlled for, DHEAS concentrations were no longer different between patients and controls (P = 0.766). The body mass index was higher (28.8 &#177; kg/m2) in the MSpa subgroup than in the other groups of patients. The detailed results on the body mass indices, lipids, and insulin resistance are the subject of a separate report (submitted for publication).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>9905</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>9916</offset><text>In the present study, we found decreased DHEAS concentrations in both women and men with RA, Spa, or UIA. This finding was previously documented in RA. With regard to Spa, Hedman et al reported normal DHEAS concentrations in 25 patients who had psoriatic arthritis, reactive arthritis, ankylosing spondylitis, or enteropathic arthritis. Both elevated and decreased DHEAS concentrations have been reported in ankylosing spondylitis. In one of the latter reports, a significant correlation between low DHEAS concentrations and a high acute-phase response was found, as was recently reported for RA. The role of sex steroids in the pathogenesis of Spa remains incompletely elucidated. Of our 29 patients with Spa, 9 had ankylosing spondylitis, 7 psoriatic arthritis, and 13 reactive or undifferentiated spondyloarthropathy. Although the DHEAS concentrations were highest in our patients with MSpa, the respective concentrations were still significantly lower than in age- and gender-matched controls.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>10914</offset><text>The number of patients enrolled in our study allowed us to control for disease-related factors, i.e. the acute-phase response, previous glucocorticoid usage, NSAID treatment, duration of disease, and insulin resistance. The overall disease activity was low in our patients (mean ESR=26 mm/hour), which may explain why the investigated disease-related parameters did not significantly predict low DHEAS concentrations except for previous glucocorticoid usage in RA women and NSAID treatments in IA men. Even after disease-related factors were controlled for, DHEAS concentrations tended to remain lower in IA women than in their control subjects. This finding indirectly supports the intriguing paradigm in which IA may select for patients with subtle adrenal insufficiency, as proposed by Masi et al. Our finding of similarly decreased concentrations in the various subsets of the disease supports the observation that risk factors for RA and inflammatory arthritides other than RA are alike. In contrast, DHEAS concentrations were no longer different in men with IA from those in their controls after disease-related parameters had been controlled for. Underactivity of the hypothalamic&#8211;pituitary&#8211;gonadal axis, with decreased testosterone production, was documented in men with RA, and this underactivity may participate in the pathogenesis in these patients. The roles of hypoadrenalism (decreased glucocorticoid as well as adrenal androgen production) and hypogonadism in the onset and persistence of disease in various IA subgroups and in both genders deserves further investigation.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>12506</offset><text>In 44 (51%) of our patients, serum DHEAS concentrations were below the 25th percentile obtained in controls and in 24 patients (28%), these levels were below normal. Robinzon and Cutolo recently attributed several side effects of glucocorticoid therapy, including catabolism, muscular atrophy, osteopenia, osteoporosis, and avascular necrosis, to the suppressant effect of these agents on the hypothalamic&#8211;pituitary&#8211;adrenal axis, resulting in decreased DHEA secretion. Also, low DHEAS concentrations constitute an independent risk factor for cardiovascular disease and recently DHEA was shown to form an intergral part of low-density lipoprotein and to protect the latter potently from oxidation. This is of interest in the present context, since a 70% excess cardiovascular mortality was reported in RA. Indeed, IA and cardiovascular disease may share a common predisposition.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>13388</offset><text>DHEA replacement is associated with improvement of physical and general wellbeing in elderly subjects and with lessening of disease activity in lupus and of osteoporosis in postmenopausal women. It constitutes part of the optimal treatment of frank adrenal insufficiency. Robinzon and Cutolo suggested the use of DHEA replacement, guided by monitoring of its concentration in the blood, in RA patients taking glucocorticoids. Although short-term DHEA replacement therapy was not associated with an improvement in disease activity in 11 patients with RA, the findings mentioned above together with our results suggest that the indications for DHEA replacement in IA should not be restricted to patients on glucocorticoids. The role of DHEA supplementation in the treatment of IA requires further study.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>14190</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>14201</offset><text>We conducted a controlled study on patients with IA, and found that DHEAS secretion is similarly reduced in individuals with RA, Spa, or UIA. After controlling for previous glucocorticoid usage, NSAID therapy, duration of disease, as well as insulin resistance, the differences in DheAS concentrations between patients and controls matched for age and sex were at least slightly reduced (low DHENAS was found to be responsible for the pathogenesis of IAO). However, we</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">title_1</infon><offset>14876</offset><text>Abbreviations</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>14890</offset><text>DHEA = dehydroepiandrosterone; DHEAS = dehydroepiandrosterone sulfate; ESR = erythrocyte sedimentation rate; FRA = rheumatoid arthritis in females; FSpa = spondyloarthropathy in females; FUIA = undifferentiated inflammatory arthritis in females; HOMAIR = homeostasis-model assessment of insulin resistance; IA = inflammatory arthritis; MRA = rheumatoid arthritis in males; MSpa = spondyloarthropathy in males; MUIA = undifferentiated inflammatory arthritis in males; NSAID = nonsteroidal anti-inflammatory drugs; RA = rheumatoid arthritis; Spa = spondyloarthropathy; UIA = undifferentiated inflammatory arthritis.</text></passage><passage><infon key="fpage">657</infon><infon key="lpage">661</infon><infon key="name_0">surname:Cutolo;given-names:M</infon><infon key="name_1">surname:Straub;given-names:RH</infon><infon key="pub-id_pmid">10976076</infon><infon key="section_type">REF</infon><infon key="source">Ann Rheum Dis</infon><infon key="type">ref</infon><infon key="volume">59</infon><infon key="year">2000</infon><offset>15504</offset><text>Recent aspects of gonadal hormone and neurotransmitter interactions with synovial and immune cells: implications in rheumatoid arthritis.</text></passage><passage><infon key="fpage">247</infon><infon key="lpage">250</infon><infon key="name_0">surname:Masi;given-names:AT</infon><infon key="name_1">surname:Chrousos;given-names:GP</infon><infon key="name_2">surname:Bornstein;given-names:ST</infon><infon key="pub-id_pmid">9972953</infon><infon key="section_type">REF</infon><infon key="source">J Rheumatol</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">1999</infon><offset>15642</offset><text>Enigmas of adrenal androgen and glucocorticoid dissociation in premenopausal onset rheumatoid arthritis.</text></passage><passage><infon key="fpage">1519</infon><infon key="lpage">1524</infon><infon key="name_0">surname:Barrett-Connor;given-names:E</infon><infon key="name_1">surname:Khaw;given-names:KT</infon><infon key="name_2">surname:Yen;given-names:SSC</infon><infon key="pub-id_pmid">2946952</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">315</infon><infon key="year">1986</infon><offset>15747</offset><text>A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease.</text></passage><passage><infon key="fpage">577</infon><infon key="lpage">581</infon><infon key="name_0">surname:Masi;given-names:AT</infon><infon key="name_1">surname:Chrousos;given-names:GP</infon><infon key="pub-id_pmid">8730107</infon><infon key="section_type">REF</infon><infon key="source">J Rheumatol</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">1996</infon><offset>15841</offset><text>hypothalamic&#8211;pituitary&#8211;adrenal-glucocorticoid axis function in rheumatoid arthritis.</text></passage><passage><infon key="fpage">282</infon><infon key="lpage">288</infon><infon key="name_0">surname:Cutolo;given-names:M</infon><infon key="name_1">surname:Foppiani;given-names:L</infon><infon key="name_2">surname:Prete;given-names:C</infon><infon key="name_3">surname:Ballarino;given-names:P</infon><infon key="name_4">surname:Sulli;given-names:A</infon><infon key="name_5">surname:Villaggio;given-names:B</infon><infon key="name_6">surname:Seriolo;given-names:B</infon><infon key="name_7">surname:Giusti;given-names:M</infon><infon key="name_8">surname:Accardo;given-names:S</infon><infon key="pub-id_pmid">9972959</infon><infon key="section_type">REF</infon><infon key="source">J Rheumatol</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">1999</infon><offset>15930</offset><text>Hypothalamic-pituitary-adreno-cortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids.</text></passage><passage><infon key="fpage">S126</infon><infon key="name_0">surname:Masi;given-names:AT</infon><infon key="name_1">surname:Chatterton;given-names:RT</infon><infon key="name_2">surname:Aldag;given-names:JC</infon><infon key="name_3">surname:Comstock;given-names:GW</infon><infon key="name_4">surname:Helzlsouer;given-names:KJ</infon><infon key="name_5">surname:Hoffman;given-names:SC</infon><infon key="name_6">surname:Malmet;given-names:RL</infon><infon key="name_7">surname:Agopian;given-names:MS</infon><infon key="section_type">REF</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">1998</infon><offset>16066</offset><text>Decreased serum dehydroepiandrosterone sulfate levels in menstruating women prior to onset of RA before age 50: independent reference laboratory assays validate previous significant results [abstract].</text></passage><passage><infon key="fpage">53</infon><infon key="lpage">62</infon><infon key="name_0">surname:Masi;given-names:AT</infon><infon key="name_1">surname:Chatterton;given-names:RT</infon><infon key="name_2">surname:Aldag;given-names:JC</infon><infon key="pub-id_pmid">10415593</infon><infon key="section_type">REF</infon><infon key="source">Ann N Y Acad Sci</infon><infon key="type">ref</infon><infon key="volume">876</infon><infon key="year">1999</infon><offset>16268</offset><text>Perturbations of hypothalamic&#8211;pituitary&#8211;gonadal axis and adrenal androgen functions in rheumatoid arthritis: an odyssey of hormonal relationships to the disease.</text></passage><passage><infon key="fpage">281</infon><infon key="lpage">285</infon><infon key="name_0">surname:Heikkila;given-names:R</infon><infon key="name_1">surname:Aho;given-names:K</infon><infon key="name_2">surname:Heliovaara;given-names:M</infon><infon key="name_3">surname:Knekt;given-names:P</infon><infon key="name_4">surname:Reunanen;given-names:A</infon><infon key="name_5">surname:Aromaa;given-names:A</infon><infon key="name_6">surname:Leino;given-names:A</infon><infon key="name_7">surname:Palosuo;given-names:T</infon><infon key="pub-id_pmid">9741311</infon><infon key="section_type">REF</infon><infon key="source">Ann Rheum Dis</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="year">1998</infon><offset>16434</offset><text>Serum androgen-anabolic hormones and the risk of rheumatoid arthritis.</text></passage><passage><infon key="fpage">597</infon><infon key="lpage">601</infon><infon key="name_0">surname:de la Torre;given-names:B</infon><infon key="name_1">surname:Hedman;given-names:M</infon><infon key="name_2">surname:Nilsson;given-names:E</infon><infon key="name_3">surname:Oleson;given-names:O</infon><infon key="name_4">surname:Throner;given-names:A</infon><infon key="pub-id_pmid">8299250</infon><infon key="section_type">REF</infon><infon key="source">Clin Exp Rheumatol</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">1993</infon><offset>16505</offset><text>Relationship between blood and joint tissue DHEAS levels in rheumatoid arthritis and osteoarthritis.</text></passage><passage><infon key="fpage">488</infon><infon key="lpage">495</infon><infon key="name_0">surname:Robinzon;given-names:B</infon><infon key="name_1">surname:Cutolo;given-names:M</infon><infon key="pub-id_pmid">10402066</infon><infon key="section_type">REF</infon><infon key="source">Rheumatology</infon><infon key="type">ref</infon><infon key="volume">38</infon><infon key="year">1999</infon><offset>16606</offset><text>Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids?</text></passage><passage><infon key="fpage">1132</infon><infon key="lpage">1137</infon><infon key="name_0">surname:Hall;given-names:J</infon><infon key="name_1">surname:Morand;given-names:EF</infon><infon key="name_2">surname:Medbak;given-names:S</infon><infon key="name_3">surname:Zaman;given-names:M</infon><infon key="name_4">surname:Perry;given-names:L</infon><infon key="name_5">surname:Goulding;given-names:NJ</infon><infon key="name_6">surname:Maddison;given-names:PJ</infon><infon key="name_7">surname:O'Hare;given-names:JP</infon><infon key="pub-id_pmid">8053951</infon><infon key="section_type">REF</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="volume">37</infon><infon key="year">1994</infon><offset>16690</offset><text>Abnormal hypothalamic&#8211;pituitary&#8211;adrenal axis function in rheumatoid arthritis. Effects of non-steroidal antiinflammatory drugs and water immersion.</text></passage><passage><infon key="fpage">125</infon><infon key="lpage">130</infon><infon key="name_0">surname:Svenson;given-names:KLG</infon><infon key="name_1">surname:Pollare;given-names:T</infon><infon key="name_2">surname:Lithell;given-names:H</infon><infon key="name_3">surname:Hallgren;given-names:R</infon><infon key="pub-id_pmid">2893241</infon><infon key="section_type">REF</infon><infon key="source">Metabolism</infon><infon key="type">ref</infon><infon key="volume">37</infon><infon key="year">1988</infon><offset>16842</offset><text>Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance.</text></passage><passage><infon key="fpage">1853</infon><infon key="lpage">1859</infon><infon key="name_0">surname:Rosmond;given-names:R</infon><infon key="name_1">surname:Dallman;given-names:MF</infon><infon key="name_2">surname:Bjorntorp;given-names:P</infon><infon key="section_type">REF</infon><infon key="source">J Clin Endocrinol</infon><infon key="type">ref</infon><infon key="volume">83</infon><infon key="year">1998</infon><offset>16947</offset><text>Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities.</text></passage><passage><infon key="fpage">315</infon><infon key="lpage">324</infon><infon key="name_0">surname:Arnett;given-names:FC</infon><infon key="name_1">surname:Edworthy;given-names:SM</infon><infon key="name_2">surname:Bloch;given-names:DA</infon><infon key="name_3">surname:McShane;given-names:DJ</infon><infon key="name_4">surname:Fries;given-names:JF</infon><infon key="name_5">surname:Cooper;given-names:NS</infon><infon key="pub-id_pmid">3358796</infon><infon key="section_type">REF</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">1988</infon><offset>17082</offset><text>The American Rheumatology Association 1987 revised criteria for the classification of rheumatoid arthritis.</text></passage><passage><infon key="fpage">107</infon><infon key="lpage">112</infon><infon key="name_0">surname:Kahn;given-names:MA</infon><infon key="name_1">surname:van der Linden;given-names:SM</infon><infon key="pub-id_pmid">2251505</infon><infon key="section_type">REF</infon><infon key="source">Semin Arthritis Rheum</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">1990</infon><offset>17190</offset><text>A wider spectrum of spondylo-arthropathies.</text></passage><passage><infon key="fpage">1643</infon><infon key="lpage">1649</infon><infon key="name_0">surname:Bonora;given-names:E</infon><infon key="name_1">surname:Kiechl;given-names:S</infon><infon key="name_2">surname:Willeit;given-names:J</infon><infon key="name_3">surname:Oberhollenzer;given-names:F</infon><infon key="name_4">surname:Egger;given-names:G</infon><infon key="name_5">surname:Targher;given-names:G</infon><infon key="name_6">surname:Alberiche;given-names:M</infon><infon key="name_7">surname:Bonadonna;given-names:RC</infon><infon key="name_8">surname:Muggeo;given-names:M</infon><infon key="pub-id_pmid">9753305</infon><infon key="section_type">REF</infon><infon key="source">Diabetes</infon><infon key="type">ref</infon><infon key="volume">47</infon><infon key="year">1998</infon><offset>17234</offset><text>Prevalence of insulin resistance in metabolic disorders. The Bruneck Study.</text></passage><passage><infon key="fpage">2158</infon><infon key="lpage">2161</infon><infon key="name_0">surname:Koh;given-names:WH</infon><infon key="name_1">surname:Pand;given-names:I</infon><infon key="name_2">surname:Samuels;given-names:A</infon><infon key="name_3">surname:Jones;given-names:S</infon><infon key="name_4">surname:Calin;given-names:A</infon><infon key="pub-id_pmid">9375877</infon><infon key="section_type">REF</infon><infon key="source">J Rheumatol</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">1997</infon><offset>17310</offset><text>Low dose amytriptyline in ankylosing spondylitis. A short term, double-blind placebo controlled study.</text></passage><passage><infon key="fpage">25</infon><infon key="lpage">30</infon><infon key="name_0">surname:Hedman;given-names:M</infon><infon key="name_1">surname:Milsson;given-names:E</infon><infon key="name_2">surname:de la Torre;given-names:B</infon><infon key="pub-id_pmid">1532354</infon><infon key="section_type">REF</infon><infon key="source">Clin Exp Rheumatol</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">1992</infon><offset>17413</offset><text>Low blood and synovial fluid levels of sulpho-conjugated steroids in rheumatoid arthritis.</text></passage><passage><infon key="fpage">340</infon><infon key="lpage">364</infon><infon key="name_0">surname:Giltay;given-names:EJ</infon><infon key="name_1">surname:van Schaardenburg;given-names:D</infon><infon key="name_2">surname:Gooren;given-names:LJ</infon><infon key="name_3">surname:Popp-Snijders;given-names:C</infon><infon key="name_4">surname:Dijkmans;given-names:BA</infon><infon key="pub-id_pmid">10415629</infon><infon key="section_type">REF</infon><infon key="source">Ann N Y Acad Sci</infon><infon key="type">ref</infon><infon key="volume">876</infon><infon key="year">1999</infon><offset>17504</offset><text>Androgens and ankylosing spondylitis: a role in the pathogenesis?</text></passage><passage><infon key="fpage">S114</infon><infon key="name_0">surname:Gutierrez-Urena;given-names:S</infon><infon key="name_1">surname:Ponce-Tellez;given-names:A</infon><infon key="name_2">surname:Tello-Jimenez;given-names:M</infon><infon key="name_3">surname:Zaragoza-Gonzalez;given-names:R</infon><infon key="name_4">surname:Ramos-Remus;given-names:C</infon><infon key="section_type">REF</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">1999</infon><offset>17570</offset><text>Serum levels of dehydroepiandrosterone (DHEA-S) in ankylosing spondylitis [abstract].</text></passage><passage><infon key="fpage">835</infon><infon key="lpage">843</infon><infon key="name_0">surname:Symmons;given-names:D</infon><infon key="name_1">surname:Harrison;given-names:B</infon><infon key="pub-id_pmid">10952736</infon><infon key="section_type">REF</infon><infon key="source">Rheumatology</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">2000</infon><offset>17656</offset><text>Early inflammatory polyarthritis: results from the Norfolk Arthritis register with a review of the literature. I. Risk factors for the development of inflammatory polyarthritis and rheumatoid arthritis.</text></passage><passage><infon key="fpage">1314</infon><infon key="lpage">1317</infon><infon key="name_0">surname:Cutolo;given-names:M</infon><infon key="name_1">surname:Balleari;given-names:E</infon><infon key="name_2">surname:Giusti;given-names:M</infon><infon key="name_3">surname:Monachesi;given-names:M</infon><infon key="name_4">surname:Accardo;given-names:S</infon><infon key="pub-id_pmid">3140823</infon><infon key="section_type">REF</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">1988</infon><offset>17859</offset><text>Sex hormone status of male patients with rheumatoid arthritis: evidence of low serum concentrations of testosterone at baseline and after human chorionic gonatotropin stimulation.</text></passage><passage><infon key="fpage">1552</infon><infon key="lpage">1561</infon><infon key="name_0">surname:Khalil;given-names:A</infon><infon key="name_1">surname:Fortin;given-names:JP</infon><infon key="name_2">surname:LeHoux;given-names:JG</infon><infon key="name_3">surname:Fulop;given-names:T</infon><infon key="pub-id_pmid">11013296</infon><infon key="section_type">REF</infon><infon key="source">J Lipid Res</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2000</infon><offset>18039</offset><text>Age-related decrease of dehydroepiandrosterone concentrations in low density lipoproteins and its role in the susceptibility of low density lipoproteins to lipid peroxidation.</text></passage><passage><infon key="fpage">241</infon><infon key="lpage">244</infon><infon key="name_0">surname:Koota;given-names:K</infon><infon key="name_1">surname:Isomaki;given-names:H</infon><infon key="name_2">surname:Mutru;given-names:O</infon><infon key="pub-id_pmid">607393</infon><infon key="section_type">REF</infon><infon key="source">Scand J Rheumatol</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">1977</infon><offset>18215</offset><text>Death rate and causes of death in RA patients during a period of five years.</text></passage><passage><infon key="fpage">1797</infon><infon key="lpage">1799</infon><infon key="name_0">surname:Mutru;given-names:O</infon><infon key="name_1">surname:Laakso;given-names:M</infon><infon key="name_2">surname:Isomaki;given-names:H</infon><infon key="name_3">surname:Koota;given-names:K</infon><infon key="section_type">REF</infon><infon key="source">Br Med J (Clin Res Ed)</infon><infon key="type">ref</infon><infon key="volume">290</infon><infon key="year">1985</infon><offset>18292</offset><text>Ten year mortality and causes of death in patients with rheumatoid arthritis.</text></passage><passage><infon key="fpage">1045</infon><infon key="lpage">1053</infon><infon key="name_0">surname:Jacobsson;given-names:LT</infon><infon key="name_1">surname:Knowler;given-names:WC</infon><infon key="name_2">surname:Pillemer;given-names:S</infon><infon key="name_3">surname:Hanson;given-names:RL</infon><infon key="name_4">surname:Pettitt;given-names:DJ</infon><infon key="name_5">surname:Nelson;given-names:RG</infon><infon key="name_6">surname:del Puente;given-names:A</infon><infon key="name_7">surname:McCance;given-names:DR</infon><infon key="name_8">surname:Charles;given-names:MA</infon><infon key="name_9">surname:Bennett;given-names:PH</infon><infon key="pub-id_pmid">8343181</infon><infon key="section_type">REF</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">1993</infon><offset>18370</offset><text>Rheumatoid arthritis and mortality. A longitudinal study in Pima Indian.</text></passage><passage><infon key="name_0">surname:Dessein;given-names:PH</infon><infon key="name_1">surname:Stanwix;given-names:AE</infon><infon key="name_2">surname:Moomal;given-names:Z</infon><infon key="section_type">REF</infon><infon key="source">Rheumatology</infon><infon key="type">ref</infon><infon key="year">2001</infon><offset>18443</offset><text>Rheumatoid arthritis and cardiovascular disease may share similar risk factors.</text></passage><passage><infon key="fpage">1360</infon><infon key="lpage">1367</infon><infon key="name_0">surname:Morales;given-names:AJ</infon><infon key="name_1">surname:Molan;given-names:JJ</infon><infon key="name_2">surname:Nelson;given-names:JE</infon><infon key="name_3">surname:Yen;given-names:SSC</infon><infon key="pub-id_pmid">7515387</infon><infon key="section_type">REF</infon><infon key="source">J Clin Endocrinol Metab</infon><infon key="type">ref</infon><infon key="volume">78</infon><infon key="year">1994</infon><offset>18523</offset><text>Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.</text></passage><passage><infon key="fpage">285</infon><infon key="lpage">289</infon><infon key="name_0">surname:van Vollenhoven;given-names:RF</infon><infon key="name_1">surname:Morabilo;given-names:LM</infon><infon key="name_2">surname:Engleman;given-names:HG</infon><infon key="name_3">surname:McGuire;given-names:JL</infon><infon key="pub-id_pmid">9489820</infon><infon key="section_type">REF</infon><infon key="source">J Rheumatol</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">1998</infon><offset>18612</offset><text>Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.</text></passage><passage><infon key="fpage">3498</infon><infon key="lpage">3505</infon><infon key="name_0">surname:Labrie;given-names:R</infon><infon key="name_1">surname:Diamond;given-names:P</infon><infon key="name_2">surname:Cusan;given-names:L</infon><infon key="name_3">surname:Gomez;given-names:JL</infon><infon key="name_4">surname:Belanger;given-names:A</infon><infon key="name_5">surname:Candas;given-names:B</infon><infon key="pub-id_pmid">9329392</infon><infon key="section_type">REF</infon><infon key="source">J Clin Endocrinol Metab</infon><infon key="type">ref</infon><infon key="volume">82</infon><infon key="year">1997</infon><offset>18720</offset><text>Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women.</text></passage><passage><infon key="fpage">1013</infon><infon key="lpage">1020</infon><infon key="name_0">surname:Wiebke;given-names:A</infon><infon key="name_1">surname:Callies;given-names:F</infon><infon key="name_10">surname:Allolio;given-names:B</infon><infon key="name_2">surname:van Vlijmen;given-names:JC</infon><infon key="name_3">surname:Koehler;given-names:I</infon><infon key="name_4">surname:Reincke;given-names:M</infon><infon key="name_5">surname:Bidlingmaier;given-names:M</infon><infon key="name_6">surname:Huebler;given-names:D</infon><infon key="name_7">surname:Oettel;given-names:M</infon><infon key="name_8">surname:Ernst;given-names:M</infon><infon key="name_9">surname:Schulte;given-names:HM</infon><infon key="pub-id_pmid">10502590</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">341</infon><infon key="year">1999</infon><offset>18840</offset><text>Dehydroepiandrosterone replacement in women with adrenal insufficiency.</text></passage><passage><infon key="section_type">FIG</infon><infon key="type">title_1</infon><offset>18912</offset><text>Figures and Tables</text></passage><passage><infon key="file">AR-3-3-183-1.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>18931</offset><text>Serum DHEAS concentrations in female controls according to their age.</text></passage><passage><infon key="file">AR-3-3-183-2.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>19001</offset><text>Serum DHEAS concentrations in male controls according to their age.</text></passage><passage><infon key="file">AR-3-3-183-3.jpg</infon><infon key="id">F3</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>19069</offset><text>Serum DHEAS concentrations in female controls (unbroken line = median; lower dotted line = 25th percentile; upper dotted line = 75th percentile) and patients (dots = RA; triangles = Spa; squares = UIA).</text></passage><passage><infon key="file">AR-3-3-183-4.jpg</infon><infon key="id">F4</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>19272</offset><text>Serum DHEAS concentrations in male controls. Symbols as in Fig. 3.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>19339</offset><text>Serum DHEAS concentrations (&#956;mol/l) in patients with IA and in controls</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center" colspan="2"&gt;Serum DHEAS (&#956;mol/l)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Gender&lt;/td&gt;&lt;td align="center"&gt;Controls&lt;/td&gt;&lt;td align="center"&gt;Patients&lt;/td&gt;&lt;td align="center"&gt;&lt;italic&gt;P&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;Women&lt;/td&gt;&lt;td align="center"&gt;3.65 &#177; 2.84&lt;/td&gt;&lt;td align="center"&gt;2.21 &#177; 2.06&lt;/td&gt;&lt;td align="center"&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Men&lt;/td&gt;&lt;td align="center"&gt;6.19 &#177; 4.12&lt;/td&gt;&lt;td align="center"&gt;3.66 &#177; 2.02&lt;/td&gt;&lt;td align="center"&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>19412</offset><text>	Serum DHEAS (&#956;mol/l)		 				 	Gender	Controls	Patients	P	 	Women	3.65 &#177; 2.84	2.21 &#177; 2.06	&lt;0.001	 	Men	6.19 &#177; 4.12	3.66 &#177; 2.02	&lt;0.001	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>19553</offset><text>Values are shown as mean &#177; SD.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>19585</offset><text>Serum DHEAS concentrations (&#956;mol/l) in subsets of IA</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align="left"&gt;IA subset&lt;/td&gt;&lt;td align="center"&gt;DHEAS&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;FRA&lt;/td&gt;&lt;td align="center"&gt;2.01 &#177; 1.50&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Fspa&lt;/td&gt;&lt;td align="center"&gt;3.04 &#177; 3.20&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;FUIA&lt;/td&gt;&lt;td align="center"&gt;1.74 &#177; 1.30&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;MRA&lt;/td&gt;&lt;td align="center"&gt;3.18 &#177; 2.07&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Mspa&lt;/td&gt;&lt;td align="center"&gt;4.61 &#177; 1.87&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;MUIA&lt;/td&gt;&lt;td align="center"&gt;2.23 &#177; 1.09&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>19639</offset><text>IA subset	DHEAS	 	FRA	2.01 &#177; 1.50	 	Fspa	3.04 &#177; 3.20	 	FUIA	1.74 &#177; 1.30	 	MRA	3.18 &#177; 2.07	 	Mspa	4.61 &#177; 1.87*	 	MUIA	2.23 &#177; 1.09	 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>19777</offset><text>*vs MUIA: P = 0.04.</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>19797</offset><text>Dependencies of DHEAS on disease-related variables in IA in females</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align="left"&gt;Variable&lt;/td&gt;&lt;td align="center"&gt;aR&lt;sup&gt;2&lt;/sup&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;italic&gt;P&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;ESR (mm/hour)&lt;/td&gt;&lt;td align="center"&gt;0.016&lt;/td&gt;&lt;td align="center"&gt;0.519&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Duration of disease (months)&lt;/td&gt;&lt;td align="center"&gt;0.015&lt;/td&gt;&lt;td align="center"&gt;0.512&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Glucocorticoid therapy&lt;/td&gt;&lt;td align="center"&gt;0.003&lt;/td&gt;&lt;td align="center"&gt;0.339&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;HOMA&lt;sub&gt;IR&lt;/sub&gt; (&#956;U.mmol/ml.l)&lt;/td&gt;&lt;td align="center"&gt;0.014&lt;/td&gt;&lt;td align="center"&gt;0.529&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;NSAID therapy&lt;/td&gt;&lt;td align="center"&gt;0.004&lt;/td&gt;&lt;td align="center"&gt;0.383&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>19865</offset><text>Variable	aR2	P	 	ESR (mm/hour)	0.016	0.519	 	Duration of disease (months)	0.015	0.512	 	Glucocorticoid therapy	0.003	0.339	 	HOMAIR (&#956;U.mmol/ml.l)	0.014	0.529	 	NSAID therapy	0.004	0.383	 	</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>20056</offset><text>aR2, adjusted R2.</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>20074</offset><text>Dependencies of DHEAS on disease-related variables in IA in males</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align="left"&gt;Variable&lt;/td&gt;&lt;td align="center"&gt;aR&lt;sup&gt;2&lt;/sup&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;italic&gt;P&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;ESR (mm/hour)&lt;/td&gt;&lt;td align="center"&gt;0.017&lt;/td&gt;&lt;td align="center"&gt;0.497&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Duration of disease (months)&lt;/td&gt;&lt;td align="center"&gt;0.004&lt;/td&gt;&lt;td align="center"&gt;0.361&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Glucocorticoid therapy&lt;/td&gt;&lt;td align="center"&gt;0.006&lt;/td&gt;&lt;td align="center"&gt;0.371&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;HOMA&lt;sub&gt;IR&lt;/sub&gt; (&#956;U.mmol/ml.l)&lt;/td&gt;&lt;td align="center"&gt;0.013&lt;/td&gt;&lt;td align="center"&gt;0.449&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;NSAID therapy&lt;/td&gt;&lt;td align="center"&gt;0.042&lt;/td&gt;&lt;td align="center"&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>20140</offset><text>Variable	aR2	P	 	ESR (mm/hour)	0.017	0.497	 	Duration of disease (months)	0.004	0.361	 	Glucocorticoid therapy	0.006	0.371	 	HOMAIR (&#956;U.mmol/ml.l)	0.013	0.449	 	NSAID therapy	0.042	0.003	 	</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>20331</offset><text>aR2, adjusted R2.</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>20349</offset><text>Dependencies of DHEAS on disease-related variables in RA in females</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align="left"&gt;Variable&lt;/td&gt;&lt;td align="center"&gt;aR&lt;sup&gt;2&lt;/sup&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;italic&gt;P&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;ESR (mm/hour)&lt;/td&gt;&lt;td align="center"&gt;0.040&lt;/td&gt;&lt;td align="center"&gt;0.109&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Duration of disease (months)&lt;/td&gt;&lt;td align="center"&gt;0.044&lt;/td&gt;&lt;td align="center"&gt;0.092&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Glucocorticoid therapy&lt;/td&gt;&lt;td align="center"&gt;0.049&lt;/td&gt;&lt;td align="center"&gt;0.037&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;HOMA&lt;sub&gt;IR&lt;/sub&gt; (&#956;U.mmol/ml.l)&lt;/td&gt;&lt;td align="center"&gt;0.023&lt;/td&gt;&lt;td align="center"&gt;0.305&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;NSAID therapy&lt;/td&gt;&lt;td align="center"&gt;0.015&lt;/td&gt;&lt;td align="center"&gt;0.433&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>20417</offset><text>Variable	aR2	P	 	ESR (mm/hour)	0.040	0.109	 	Duration of disease (months)	0.044	0.092	 	Glucocorticoid therapy	0.049	0.037	 	HOMAIR (&#956;U.mmol/ml.l)	0.023	0.305	 	NSAID therapy	0.015	0.433	 	</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>20608</offset><text>aR2, adjusted R2.</text></passage><passage><infon key="file">T6.xml</infon><infon key="id">T6</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>20626</offset><text>Dependencies of DHEAS on disease-related variables in Spa in males</text></passage><passage><infon key="file">T6.xml</infon><infon key="id">T6</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align="left"&gt;Variable&lt;/td&gt;&lt;td align="center"&gt;aR&lt;sup&gt;2&lt;/sup&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;italic&gt;P&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;ESR (mm/hour)&lt;/td&gt;&lt;td align="center"&gt;0.025&lt;/td&gt;&lt;td align="center"&gt;0.172&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Duration of disease (months)&lt;/td&gt;&lt;td align="center"&gt;0.002&lt;/td&gt;&lt;td align="center"&gt;0.259&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Glucocorticoid therapy&lt;/td&gt;&lt;td align="center"&gt;0.023&lt;/td&gt;&lt;td align="center"&gt;0.160&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;HOMA&lt;sub&gt;IR&lt;/sub&gt; (&#956;U.mmol/ml.l)&lt;/td&gt;&lt;td align="center"&gt;0.152&lt;/td&gt;&lt;td align="center"&gt;0.083&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;NSAID therapy&lt;/td&gt;&lt;td align="center"&gt;0.167&lt;/td&gt;&lt;td align="center"&gt;0.073&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>20693</offset><text>Variable	aR2	P	 	ESR (mm/hour)	0.025	0.172	 	Duration of disease (months)	0.002	0.259	 	Glucocorticoid therapy	0.023	0.160	 	HOMAIR (&#956;U.mmol/ml.l)	0.152	0.083	 	NSAID therapy	0.167	0.073	 	</text></passage><passage><infon key="file">T6.xml</infon><infon key="id">T6</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>20884</offset><text>aR2, adjusted R2.</text></passage></document></collection>